These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 31871269

  • 1. Mechanisms of Entrectinib Resistance in a Neuroblastoma Xenograft Model.
    MacFarland SP, Naraparaju K, Iyer R, Guan P, Kolla V, Hu Y, Tan K, Brodeur GM.
    Mol Cancer Ther; 2020 Mar; 19(3):920-926. PubMed ID: 31871269
    [Abstract] [Full Text] [Related]

  • 2. Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model.
    Iyer R, Wehrmann L, Golden RL, Naraparaju K, Croucher JL, MacFarland SP, Guan P, Kolla V, Wei G, Cam N, Li G, Hornby Z, Brodeur GM.
    Cancer Lett; 2016 Mar 28; 372(2):179-86. PubMed ID: 26797418
    [Abstract] [Full Text] [Related]

  • 3. Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma.
    Pacenta HL, Macy ME.
    Drug Des Devel Ther; 2018 Mar 28; 12():3549-3561. PubMed ID: 30425456
    [Abstract] [Full Text] [Related]

  • 4. Combating autophagy is a strategy to increase cytotoxic effects of novel ALK inhibitor entrectinib in neuroblastoma cells.
    Aveic S, Pantile M, Seydel A, Esposito MR, Zanon C, Li G, Tonini GP.
    Oncotarget; 2016 Feb 02; 7(5):5646-63. PubMed ID: 26735175
    [Abstract] [Full Text] [Related]

  • 5. Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor.
    Menichincheri M, Ardini E, Magnaghi P, Avanzi N, Banfi P, Bossi R, Buffa L, Canevari G, Ceriani L, Colombo M, Corti L, Donati D, Fasolini M, Felder E, Fiorelli C, Fiorentini F, Galvani A, Isacchi A, Borgia AL, Marchionni C, Nesi M, Orrenius C, Panzeri A, Pesenti E, Rusconi L, Saccardo MB, Vanotti E, Perrone E, Orsini P.
    J Med Chem; 2016 Apr 14; 59(7):3392-408. PubMed ID: 27003761
    [Abstract] [Full Text] [Related]

  • 6. Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer.
    Ku BM, Bae YH, Lee KY, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.
    Invest New Drugs; 2020 Apr 14; 38(2):360-368. PubMed ID: 31124056
    [Abstract] [Full Text] [Related]

  • 7. Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications.
    Ardini E, Menichincheri M, Banfi P, Bosotti R, De Ponti C, Pulci R, Ballinari D, Ciomei M, Texido G, Degrassi A, Avanzi N, Amboldi N, Saccardo MB, Casero D, Orsini P, Bandiera T, Mologni L, Anderson D, Wei G, Harris J, Vernier JM, Li G, Felder E, Donati D, Isacchi A, Pesenti E, Magnaghi P, Galvani A.
    Mol Cancer Ther; 2016 Apr 14; 15(4):628-39. PubMed ID: 26939704
    [Abstract] [Full Text] [Related]

  • 8. TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts.
    Croucher JL, Iyer R, Li N, Molteni V, Loren J, Gordon WP, Tuntland T, Liu B, Brodeur GM.
    Cancer Chemother Pharmacol; 2015 Jan 14; 75(1):131-41. PubMed ID: 25394774
    [Abstract] [Full Text] [Related]

  • 9. Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in ETV6-NTRK3-Positive Acute Myeloid Leukemia.
    Smith KM, Fagan PC, Pomari E, Germano G, Frasson C, Walsh C, Silverman I, Bonvini P, Li G.
    Mol Cancer Ther; 2018 Feb 14; 17(2):455-463. PubMed ID: 29237803
    [Abstract] [Full Text] [Related]

  • 10. Foretinib Overcomes Entrectinib Resistance Associated with the NTRK1 G667C Mutation in NTRK1 Fusion-Positive Tumor Cells in a Brain Metastasis Model.
    Nishiyama A, Yamada T, Kita K, Wang R, Arai S, Fukuda K, Tanimoto A, Takeuchi S, Tange S, Tajima A, Furuya N, Kinoshita T, Yano S.
    Clin Cancer Res; 2018 May 15; 24(10):2357-2369. PubMed ID: 29463555
    [Abstract] [Full Text] [Related]

  • 11. Entrectinib: a potent new TRK, ROS1, and ALK inhibitor.
    Rolfo C, Ruiz R, Giovannetti E, Gil-Bazo I, Russo A, Passiglia F, Giallombardo M, Peeters M, Raez L.
    Expert Opin Investig Drugs; 2015 May 15; 24(11):1493-500. PubMed ID: 26457764
    [Abstract] [Full Text] [Related]

  • 12. Effect of CEP-751 (KT-6587) on neuroblastoma xenografts expressing TrkB.
    Evans AE, Kisselbach KD, Liu X, Eggert A, Ikegaki N, Camoratto AM, Dionne C, Brodeur GM.
    Med Pediatr Oncol; 2001 Jan 15; 36(1):181-4. PubMed ID: 11464878
    [Abstract] [Full Text] [Related]

  • 13. Trk inhibitor attenuates the BDNF/TrkB-induced protection of neuroblastoma cells from etoposide in vitro and in vivo.
    Li Z, Zhang Y, Tong Y, Tong J, Thiele CJ.
    Cancer Biol Ther; 2015 Jan 15; 16(3):477-83. PubMed ID: 25700942
    [Abstract] [Full Text] [Related]

  • 14. GZD2202, a novel TrkB inhibitor, suppresses BDNF-mediated proliferation and metastasis in neuroblastoma models.
    Zou J, Zhang Z, Xu F, Cui S, Qi C, Luo J, Wang Z, Lu X, Tu Z, Ren X, Song L, Ding K.
    J Drug Target; 2019 Apr 15; 27(4):442-450. PubMed ID: 30301369
    [Abstract] [Full Text] [Related]

  • 15. Neuropeptide Y receptor Y5 as an inducible pro-survival factor in neuroblastoma: implications for tumor chemoresistance.
    Czarnecka M, Trinh E, Lu C, Kuan-Celarier A, Galli S, Hong SH, Tilan JU, Talisman N, Izycka-Swieszewska E, Tsuei J, Yang C, Martin S, Horton M, Christian D, Everhart L, Maheswaran I, Kitlinska J.
    Oncogene; 2015 Jun 11; 34(24):3131-43. PubMed ID: 25132261
    [Abstract] [Full Text] [Related]

  • 16. Entrectinib Induces Apoptosis and Inhibits the Epithelial-Mesenchymal Transition in Gastric Cancer with NTRK Overexpression.
    Sohn SH, Sul HJ, Kim BJ, Kim HS, Zang DY.
    Int J Mol Sci; 2021 Dec 30; 23(1):. PubMed ID: 35008821
    [Abstract] [Full Text] [Related]

  • 17. Entrectinib reverses cytostatic resistance through the inhibition of ABCB1 efflux transporter, but not the CYP3A4 drug-metabolizing enzyme.
    Vagiannis D, Yu Z, Novotna E, Morell A, Hofman J.
    Biochem Pharmacol; 2020 Aug 30; 178():114061. PubMed ID: 32497550
    [Abstract] [Full Text] [Related]

  • 18. Molecular Iodine/Cyclophosphamide Synergism on Chemoresistant Neuroblastoma Models.
    Álvarez-León W, Mendieta I, Delgado-González E, Anguiano B, Aceves C.
    Int J Mol Sci; 2021 Aug 19; 22(16):. PubMed ID: 34445656
    [Abstract] [Full Text] [Related]

  • 19. Small molecule inhibitor agerafenib effectively suppresses neuroblastoma tumor growth in mouse models via inhibiting ERK MAPK signaling.
    Li H, Yu Y, Zhao Y, Wu D, Yu X, Lu J, Chen Z, Zhang H, Hu Y, Zhai Y, Su J, Aheman A, De Las Casas A, Jin J, Xu X, Shi Z, Woodfield SE, Vasudevan SA, Agarwal S, Yan Y, Yang J, Foster JH.
    Cancer Lett; 2019 Aug 10; 457():129-141. PubMed ID: 31100410
    [Abstract] [Full Text] [Related]

  • 20. Brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from chemotherapy-induced apoptosis via phosphatidylinositol 3'-kinase pathway.
    Jaboin J, Kim CJ, Kaplan DR, Thiele CJ.
    Cancer Res; 2002 Nov 15; 62(22):6756-63. PubMed ID: 12438277
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.